Association between an interleukin-6 promoter and 3' flanking region haplotype and reduced Alzheimer's disease risk in a German population

Neuroscience Letters

Volumn 283, Issue 2, 2000, Pages 109-112

  Bagli, Metin ^a   Papassotiropoulos, Andreas ^a   Knapp, Michael ^a   Jessen, Frank ^a   Luise Rao, Marie ^a   Maier, Wolfgang ^a   Heun, Reinhard ^a  

^a UNIVERSITY OF BONN   (Germany)

Author keywords

Alzheimer's disease; Gene gene interaction; Interleukin 6; Linkage disequilibrium; Polymorphism; Promoter; Variable number of tandem repeat

Indexed keywords

INTERLEUKIN 6;

ADULT; AGED; ALLELE; ALZHEIMER DISEASE; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DISEASE ASSOCIATION; DNA FLANKING REGION; FEMALE; GENE EXPRESSION; GENE LINKAGE DISEQUILIBRIUM; GENETIC POLYMORPHISM; GERMANY; HAPLOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; POPULATION RESEARCH; PRIORITY JOURNAL; PROMOTER REGION; RISK; TANDEM REPEAT;

ALLELES; ALZHEIMER DISEASE; EUROPEAN CONTINENTAL ANCESTRY GROUP; GENE EXPRESSION REGULATION; GENE FREQUENCY; GENOTYPE; GERMANY; HAPLOTYPES; HUMANS; INTERLEUKIN-6; MINISATELLITE REPEATS; POLYMORPHISM, GENETIC; PROMOTER REGIONS (GENETICS); REFERENCE VALUES; REGRESSION ANALYSIS; RISK FACTORS;

EID: 0034616230     PISSN: 03043940     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0304-3940(00)00917-4     Document Type: Article

References (18)

1. Bowcock A.M., Ray A., Erlich H., Sehgal P.B. Rapid detection and sequencing of alleles in the 3′ flanking region of the interleukin-6 gene. Nucleic Acids. Res. 17:1989;6855-6864.
2. Breitner J.C. Inflammatory processes and antiinflammatory drugs in Alzheimer's disease: a current appraisal. Neurobiol. Aging. 17:1989;789-794.
3. Campbell I.L., Stalder A.K., Chiang C.S., Bellinger R., Heyser C.J., Steffensen S., Masliah E., Powell H.C., Gold L.H., Henriksen S.J., Siggins G.R. Transgenic models to assess the pathogenic actions of cytokines in the central nervous system. Mol. Psychiatry. 2:1997;125-129.
4. Fishman D., Faulds G., Jeffery R., Mohamed-Ali V., Yudkin J.S., Humphries S., Woo P. The effect of novel polymorphisms in the interleukin-6 (IL-6) gene on IL-6 transcription and plasma IL-6 levels, and an association with systemic-onset juvenile chronic arthritis. J. Clin. Invest. 102:1998;1369-1376.
5. Gruol D.L., Nelson T.E. Physiological and pathological roles of interleukin-6 in the central nervous system. Mol. Neurobiol. 15:1997;307-339.
6. Hampel H., Schoen D., Schwarz M.J., Kotter H.U., Schneider C., Sunderland T., Dukoff R., Levy J., Padberg F., Stubner S., Buch K., Muller N., Möller H.J. Interleukin-6 is not altered in cerebrospinal fluid of first-degree relatives and patients with Alzheimer's disease. Neurosci. Lett. 228:1997;143-146.
7. Lanzrein A.S., Johnston C.M., Perry V.H., Jobst K.A., King E.M., Smith A.D. Longitudinal study of inflammatory factors in serum, cerebrospinal fluid, and brain tissue in Alzheimer disease: interleukin-1beta, interleukin-6, interleukin-1 receptor antagonist, tumor necrosis factor-alpha, the soluble tumor necrosis factor receptors I and II, and alpha1-antichymotrypsin. Alzheimer Dis. Assoc. Disord. 12:1998;215-227.
8. Maes M., Meltzer H.Y., Bosmans E., Bergmans R., Vandoolaeghe E., Ranjan R., Desnyder R. Increased plasma concentrations of interleukin-6, soluble interleukin-6, soluble interleukin-2 and transferrin receptor in major depression. J. Affect. Disord. 34:1995;301-309.
9. McGeer P.L., McGeer E., Rogers J., Sibley J. Anti-inflammatory drugs and Alzheimer disease. Lancet. 335:1990;1037.
10. McKhann G., Drachman D., Folstein M., Katzman R., Price D., Stadlan E.M. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology. 34:1984;939-944.
11. Murray R.E., McGuigan F., Grant S.F., Reid D.M., Ralston S.H. Polymorphisms of the interleukin-6 gene are associated with bone mineral density. Bone. 21:1997;89-92.
12. Papassotiropoulos A., Bagli M., Jessen F., Bayer T.A., Maier W., Rao M.L., Heun R. A genetic variation of the inflammatory cytokine interleukin-6 delays the initial onset and reduces the risk for sporadic Alzheimer's disease. Ann. Neurol. 45:1999;666-668.
13. Rogers J., Webster S., Lue L.F., Brachova L., Civin W.H., Emmerling M., Shivers B., Walker D., McGeer P. Inflammation and Alzheimer's disease pathogenesis. Neurobiol. Aging. 17:1996;681-686.
14. Singh V.K. Studies of neuroimmune markers in Alzheimer's disease. Mol. Neurobiol. 9:1994;73-81.
15. Singh V.K., Guthikonda P. Circulating cytokines in Alzheimer's disease. J. Psychiatry Res. 31:1997;657-660.
16. Strauss S., Bauer J., Ganter U., Jonas U., Berger M., Volk B. Detection of interleukin-6 and alpha 2-macroglobulin immunoreactivity in cortex and hippocampus of Alzheimer's disease patients. Lab. Invest. 66:1992;223-230.
17. Terwilliger J.D., Ott J. Linkage disequilibrium between alleles at marker loci. Terwilliger J.D., Ott J. Handbook of Human Genetic Linkage. 1994;189-198 The Johns Hopkins University Press, Baltimore.
18. Zhao B., Schwartz J.P. Involvement of cytokines in normal CNS development and neurological diseases: recent progress and perspectives. J. Neurosci. Res. 52:1998;7-16.